Evidence map›Paper›PMID 34697855›Full record

ArticleHead & neck2022

Hyperintensity of integrin-targeted fluorescence agent IntegriSense750 accurately predicts flap necrosis compared to Indocyanine green.

Melanie D Hicks, Alyssa K Ovaitt, Jason C Fleming, Anna G Sorace, Patrick N Song, Ameer Mansur, Yolanda E Hartman Bs, Eben L Rosenthal, Jason M Warram, Carissa M Thomas

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Melanie D HicksDepartment of Otolaryngology - Head & Neck Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-7162-3008
Alyssa K OvaittDepartment of Otolaryngology - Head & Neck Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Jason C FlemingLiverpool Head and Neck Centre, Aintree University Hospital, University of Liverpool, Liverpool, UK.
Anna G SoraceDepartment of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Patrick N SongDepartment of Radiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Ameer MansurDepartment of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Yolanda E Hartman BsDepartment of Otolaryngology - Head & Neck Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Eben L RosenthalDepartment of Otolaryngology - Head & Neck Surgery, Stanford University, Stanford, California, USA.
Jason M WarramDepartment of Otolaryngology - Head & Neck Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Carissa M ThomasDepartment of Otolaryngology - Head & Neck Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
University of Alabama at Birmingham · USStanford University · USUniversity of Liverpool · GB

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Reduction of Tumor-Positive Margins in Oncology SurgeryR37CA245157 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Jason Morgan Warram · 2021 to 2026
$3.2M
Personalizing immunotherapy in HER2+ breast cancer through quantitative imagingR01CA240589 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SORACE, ANNA C · 2020 to 2023
$1.6M
Combination optical imaging to guide transoral laser microsurgery in larynx cancerR21CA292196 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PANUGANTI, BHARAT, WARRAM, JASON MORGAN · 2024 to 2024
$375k
NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA240589NCI NIH HHS R21 CA292196NCI NIH HHS R37 CA245157
6 · The paper itself

Abstract

backgroundFlap necrosis is a feared complication of reconstructive surgery. Current methods of prediction using Indocyanine green (ICG) lack specificity. IntegriSense750 is a fluorescence agent that binds sites of vascular remodeling. We hypothesized that IntegriSense750 better predicts flap compromise compared to ICG.

methodsFifteen mice underwent lateral thoracic artery axial flap harvest. Mice received an injection of ICG (n = 7) or IntegriSense750 (n = 8) daily from postoperative days (POD) 0-3 and were imaged daily. Mean signal-to-background ratios quantified the change in fluorescence as necrosis progressed.

resultsMean signal-to-background ratio was significantly higher for IntegriSense750 compared to ICG on POD0 (1.47 ± 0.17 vs. 0.86 ± 0.21, p = 0.01) and daily through POD3 (2.12 ± 0.70 vs. 0.96 ± 0.29, p < 0.001).

conclusionsIntegriSense750 demonstrates increased signal-to-background ratio at areas of flap distress compared to ICG which may increase identification of flap necrosis and improve patient outcomes.

Indexed as

Indocyanine GreenIntegrinsAnimalsColoring AgentsFluorescenceMiceNecrosisSurgical FlapsColoring AgentsIndocyanine GreenIntegrinsaxial pattern flapflap necrosisIndocyanine greenIntegriSense750murine flap model

Identifiers

PMID34697855
PMCPMC8688316
OpenAlexW3209699041

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.